AstraZeneca hit by patent expiries as sales slump
Drugmaker AstraZeneca has showed it is still languishing in intensive care after patent expiries triggered an 8 per per cent fall in sales to $25.7
Despite new chief executive Pascal Soriot’s recent string of acquisitions to boost Astra’s pipeline, the pharmaceuticals giant admitted that it expects revenues to fall again this year by “a low-to-mid-single-digit percentage”.
Astra is suffering from blockbuster drugs, including cholesterol-buster Crestor and heartburn and ulcer treatment Nexium, facing cheaper, generic competition in Australia and Europe respectively.
Those patent expiries, as well as the cost of acquisitions, including spending up to $4.1 billion buying out rival Bristol-Myers Squibb’s stake in a diabetes-medicine development venture, saw Astra’s pre-tax profit crash 57 per cent to $3.3 billion in 2013.
In the crucial United States market, Astra’s revenues fell 7 per cent in the last three months of 2013, while in Europe, where treatments including anti-psychotic drug Seroquel IR dropped out of patent, sales lost 2 per cent in the same period.
The US picture is set to worsen this year: from May, Nexium will face generic competition. Astra admitted that US healthcare reforms, which force drugmakers to pay annual fees, had cost $318 million in the fourth quarter.
Soriot, who has cut Astra’s headcount by more than 11,000 over two years, said: “Our financial performance for 2013 reflects the ongoing impact from the loss of exclusivity for several key brands. In the near term these headwinds will remain challenging, however I am confident that we can return to growth… and expect our 2017 revenues will be broadly in line with 2013.”
He also said Astra’s late-stage pipeline of drugs that are close to being put forward for regulatory approval has nearly doubled.
The shares fell 3.5%, or 135.5p, to 3741.5p.
Is your name now 'banned' in Saudi Arabia?
Oscar Pistorius trial: Photographs of Paralympian splattered in blood shown in court
Seth Rogen compiles list of all the celebrities he’s got high with
Missing Malaysia Airlines Flight MH370: Satellite ‘pings sent five hours after contact was lost' the only clue in hunt for £160m plane
Missing Malaysia Airlines Flight MH370: Plane's communications were deliberately disabled says prime minister Razak as new radar evidence points to hijacking
Katie Hopkins continues campaign to become Britain's most hated talking head with poorly timed Bob Crow tweet
No EU referendum under Labour: Ed Miliband to reveal that vote on membership is ‘unlikely’ in next Parliament if party wins power
Grace Dent: Who cares if she spells it Barraco Barner? Gemma Worrall is more employable than some bookish arts graduate
Europeans have ‘got whiter’ due to natural selection in past 5,000 years, scientists say
Fracking is turning the US into a bigger oil producer than Saudi Arabia
The rise of Ukip: Study warns Labour that Eurosceptic party's electoral base now 'more working class than any of the main parties'
- 1 Is your name now 'banned' in Saudi Arabia?
- 2 Best films on Netflix: 32 movies that will put an end to your scrolling
- 3 Saving a crushed egg with tape and glue: Why you should care about the kakapo
- 4 Istanbul protesters take 'Ellen selfie' from the back of a police van
- 5 Lady Gaga has struggled with eating disorders in the past, so it's indefensible that she's glamourising bulimia in her SXSW set
iJobs Money & Business
£35000 - £43000 per annum + Bonus and Benefits: Harrington Starr: A global lea...
£50000 - £60000 per annum: Harrington Starr: Linux Systems Administrator - UNI...
£32000 - £36000 per annum + generous benefits: Pro-Recruitment Group: * TAX * ...
£37000 - £40000 per annum + £20000 benefits package: Pro-Recruitment Group: **...